Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Greggs delays Moorhead appointment until WH Smith review completed

(Sharecast News) - Greggs said on Thursday that Robert Moorhead has asked to defer his appointment to the board after a review into WH Smith has been completed. The bakery chain announced at the end of last month that it was appointing Moorhead as an independent non-executive director with effect from 1 October.

Moorhead was chief financial officer and chief operating officer of WH Smith before retiring from the board in November 2024.

Greggs said that Kate Ferry, who had been due to retire at the end of August, will stay on as a non-executive director and continue to chair the Audit Committee.

WH Smith shares tanked earlier this month as the retailer said it had instructed Deloitte to undertake an "independent and comprehensive" review, after it uncovered an accounting overstatement of around £30m for North America trading profit.

It said at the time that the overstatement was mainly due to "the accelerated recognition of supplier income" in the North America division.

Independent retail analyst Nick Bubb noted that "after the accounting scandal that blew up last week at WH Smith...fingers were pointed at the role of the current CFO, Max Izzard, but he has only been in place for less than year (he joined WH Smith from Burberry on Sept 1 and became CFO on Nov 1)".

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.